Formulation and Characterization of Antigen-loaded PLGA Nanoparticles for Efficient Cross-priming of the Antigen by Lee, Young-Ran et al.
IMMUNE NETWORK http://www.ksimm.or.kr Volume 11 Number 3 June 2011
DOI 10.4110/in.2011.11.3.163
pISSN 1598-2629    eISSN 2092-6685
163
ORIGINAL ARTICLE
Received on May 23, 2011. Revised on June 2, 2011. Accepted on June 10, 2011.
CC This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial 
License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribu-
tion, and reproduction in any medium, provided the original work is properly cited.
*Corresponding Author. Tel: 82-43-261-2826; Fax: 82-43-268-2732; E-mail: cklee@chungbuk.ac.kr
Keywords: PLGA, Nanoparticle, Opsonization, Cross-priming
Formulation and Characterization of Antigen-loaded PLGA 
Nanoparticles for Efficient Cross-priming of the Antigen
Young-Ran Lee
1, Young-Hee Lee
1, Sun-A Im
1, Kyungjae Kim
2 and Chong-Kil Lee
1*
1College of Pharmacy, Chungbuk National University, Cheongju 361-763, 
2College of Pharmacy, ShamYook University, Seoul 139-742, 
Korea
Background: Nanoparticles (NPs) prepared from biodegrad-
able polymers, such as poly (D,L-lactic acid-co-glycolic acid) 
(PLGA), have been studied as vehicles for the delivery of an-
tigens to phagocytes. This paper describes the preparation 
of antigen-loaded PLGA-NPs for efficient cross-priming. 
Methods:  NPs containing a similar amount of ovalbumin 
(OVA) but different sizes were produced using a micro-
mixer-based W/O/W solvent evaporation procedure, and 
the efficiency of the NPs to induce the cross-presentation of 
OVA peptides were examined in dendritic cells (DCs). 
Cellular uptake and biodistribution studies were performed 
using fluorescein isothiocyanate (FITC)-loaded NPs in mice. 
Results: The NPs in the range of 1.1∼1.4μm in size were 
the most and almost equally efficient in inducing the cross- 
presentation of OVA peptides via H-2K
b molecules. Cellular 
uptake and biodistribution studies showed that opsonization 
of the NPs with mouse IgG greatly increased the percentage 
of FITC-positive cells in the spleen and lymph nodes. The ma-
jor cell type of FITC-positive cells in the spleen was macro-
phages, whereas that of lymph nodes was DCs. Conclusion: 
These results show that IgG-opsonized PLGA-NPs with a 
mean size of 1.1μm would be the choice of biodegradable 
carriers for the targeted-delivery of protein antigens for 
cross-priming in vivo.
[Immune Network 2011;11(3):163-168]
INTRODUCTION
Nano- and microparticles prepared from biodegradable poly-
mers, such as PLGA and poly(L-lactic acid) (PLG) have been 
studied extensively for the sustained delivery of therapeutic 
agents  including  DNA,  proteins  and  low  molecular  weight 
pharmacological agents (1,2). Nano- and microparticles pre-
pared from PLGA and PLG have also been studied as a ve-
hicle  to  deliver  encapsulated  antigens  to  phagocytes  (3-5). 
PLGA-microspheres have been shown to deliver antigens to 
APCs  efficiently  and  generate  Th1-type  immune  responses 
even against poor immunogens (6,7). Antigens encapsulated 
with PLGA were at least 100 times more effectively presented 
by MHC-I molecules on DCs compared to the soluble form 
of the antigens (8). One of the major advantages of encapsu-
lation would also be the protection of the antigen or the drug 
from  premature  release  and  degradation  (1).
    Recent studies have shown that PLGA particle-mediated an-
tigen  delivery  enhances  and  prolongs  the  MHC  class  I-re-
stricted  presentation  of  the  exogenous  antigens  (cross-pre-
sentation)  in  DCs  (5,9).  The  uptake  of  PLGA-particles  by 
phagocytes is influenced by a range of factors, such as the 
size,  surface  properties  and  concentration  in  the  medium 
(10-12). Particles between 3∼10μm in size were preferen-
tially  internalized  by  APCs  (13,14).  Although  many  studies 
have  reported  on  the  uptake  of  PLGA  particles  by  phag-
ocytes,  relatively  little  is  known  about  the  relationship  be-
tween the particle size and cross-presentation-inducing ability 
of the particles. The in vivo specific targeting of PLGA-encap-
sulated antigens to professional APCs is essential for the effi-
cient  induction  of  antigen-specific  CD8  T  cell  responses. 
Although neutrophils are the most aggressive phagocytic cells 
in the blood, they do not serve as professional APCs. Because APC Targeting of Ag with PLGA-nanoparticles
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professional APCs express receptors for the Fc region of IgG, 
opsonization of PLGA particles with IgG might be a way of 
preferentially  targeting  particles  to  professional  APCs.
    In the present study, OVA-containing PLGA particles with 
different sizes but containing similar amounts of OVA were 
generated  and  the  cross-presentation-inducing  activities  in 
DCs were compared. In addition, the effect of opsonizing the 
PLGA  particles  with  IgG  on  the  cellular  uptake  and  bio-
distribution  in  mice  was  examined.
MATERIALS AND METHODS
Cells and cell culture
A T cell hybridoma, B3Z86/90.14 (B3Z), was kindly provided 
by Dr. Nilabh Shastri (University of California, Berkeley, CA) 
and T cell hybridomas, CD8 OVA1.3, were kindly provided 
by Dr. Clifford V. Harding (Case Western Reserve University, 
Cleveland,  OH)  (15,16).  Bone  marrow  (BM)-derived  DCs 
were generated from mouse bone marrow cells, as described 
previously (8). Briefly, BM cells obtained from the femurs of 
BALB/c mouse were cultured in a 6-well plate (5×10
6/well) 
i n  a  c u l t u r e  m e d i u m  s u p p l e m e n t e d  w i t h  2 0 0  U / m l  r m G M -  
CSF.  At  days  3  and  4  from  the  initiation  of  culture,  the 
non-adherent  cells  were  discarded  by  replacing  the  culture 
medium  with  fresh  medium  containing  the  cytokines  after 
gentle shaking. The DCs were harvested by gentle pipetting 
a t  d a y  6 .
Preparation of PLGA particles
Particles  containing  OVA  were  prepared,  as  described  pre-
viously with minor modifications (12). Briefly, 400μl of OVA 
(100 mg/ml) was added to 2 ml of ethyl acetate containing 
200 mg of poly(lactic-co-glycolic acid) (PLGA, Sigma-Aldrich). 
The mixture was then stirred at 20,000 rpm (Homogeniser, 
IKA, Japan) in the presence or absence of simultaneous soni-
cation (Ultrasonic bath: 500 W, 30 kHz, BRANSON). After 3 
min of emulsification, 8 ml of an aqueous solution of poly-
vinyl alcohol (PVA, 5%) was added to the w/o emulsion to 
form a w/o/w double emulsion, which was stirred for 5 min. 
To solidify the nanoparticles, the organic solvent was evapo-
rated by stirring the double emulsion with 200 ml of an aque-
ous solution of 0.1% PVA at 500 rpm for 2 h. For the com-
plete removal of ethyl acetate, the dispersion of nanoparticles 
was concentrated to approximately half the volume using a 
rotary evaporator at 40
oC. The  resulting nanoparticles  were 
centrifuged at 3,000 rpm for 20 min, and washed twice with 
phosphate-buffered saline (PBS). The mean size of the par-
ticles  was  measured  using  a  particle  size  analyzer  (ELS-Z, 
Otsuka, Japan). The OVA concentration was determined us-
ing a micro-bicinchoninic acid assay kit (Pierce, Rockford, IL) 
after lysing the nanoparticles in a lysis buffer containing 0.1% 
SDS  and  0.1  N  NaOH.  Nanoparticles  containing  both  OVA 
and fluorescein isothiocyanate (FITC) were prepared by add-
ing FITC (final, 5 mg/ml) to ethyl acetate along with PLGA 
(final, 5%). The surface morphology of the formulated NPs 
was  visualized by scanning  electron microscopy (LEO-1530, 
Carl  Zeiss,  Germany).
Opsonization with IgG
OVA-specific mouse IgG (mIgG) was attached covalently to 
the  nanoparticles  using  (1-ethyl-3-(3-dimethylaminopropyl)- 
carbodiimide) (EDC, Pierce, Rockford, IL, USA) as previously 
described (12). Briefly, 4.5μg of EDC was added to a 360μl 
mixture of 400μg nanoparticles (as OVA concentration) and 
400μg  mIgG.  The  reaction  mixture  was  incubated  for  2  h 
by tapping at room temperature. An excess linking reagent 
and soluble byproducts were separated by centrifugation at 
15,000 rpm for 10 min, and the nanoparticles were washed 
three  times  with  1  ml  PBS,  pH  7.4.
MHC class I-restricted presentation assay
The  DCs  were  added to  a  96-well microtiter plate  (1×10
5/ 
well) and were then added with the nanoparticles. The plate 
was incubated for 2 or 18 h at 37
oC,washed twice with 300 
μl / w e l l  o f  p r e - w a r m e d  P B S  a n d  f i x e d  w i t h  1 0 0μl/well  of 
ice-cold  1.0%  paraformaldehyde  for  5  min  at  room  tem-
perature.  The  plate  was  then  washed  three  times  with  300 
μl/well of PBS. Class I MHC-complexed OVA peptide quan-
tities were assessed using LacZ T cell activation assays or by 
IL-2  secretion  assays  after  culturing  the  paraformaldehyde- 
fixed DCs with B3Z cells (2×10
5/well) for 4 h or with CD8 
OVA1.3 cells (2×10
5/well) for 18 h, as described previously 
(8,17).
In vitro release of OVA
Four milligrams of OVA-NPs were dispersed in 4 ml of PBS 
(pH 7.2) containing 0.02% sodium azide. The suspension was 
then aliquoted to a 500μl/microfuge tube, and the microfuge 
tubes were kept at 37
oC or 4
oC. At the indicated days, the 
microfuge tubes were centrifuged at 15,000 rpm for 10 min, 
and the supernatants were transferred to new tubes. The su-
pernatants were filtered through a membrane filter (pore size APC Targeting of Ag with PLGA-nanoparticles
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Table I. Effects of the homogenization speed and sonication on the size and physicochemical properties of OVA-loaded nanospheres
Homogenization 
speed (rpm) 
Sonication 
Average particle 
size (nm) 
Polydispersity 
index 
Zeta potential 
(mV) 
OVA encapsulation 
efficiency (%) 
11,000 ＋ 765.1 0.435 −4.47 24.8
− 1,800.2 0.440 −5.36 23.0
15,000 ＋ 581.8 0.286 −4.04 24.0
− 1,436.0 0.180 −5.06 25.0
20,000 ＋ 561.4 0.250 −3.10 24.8
− 1,116.8 0.027 −4.16 22.0
Figure 1. Release profile of OVA from OVA-loaded NPs. (A) Scanning 
electron microscopy showing the surface morphology of NPs with a
mean size of 1.1μm. (B) Four milligrams of the OVA-NPs were 
dispersed in 4 ml of PBS containing 0.02% sodium azide, and then
were kept at 37
oC, or 4
oC. At the indicated days, the supernatants 
were collected after centrifugation, and then the protein contents were
analyzed using a micro-bicinchoninic acid assay.
0.22μm), and then the protein content was analyzed using 
a  micro-bicinchoninic  acid  assay  kit  (Pierce).
In vivo distribution of NP
C57BL/6 mice were injected i.p. with 100μg of NPs contain-
ing both OVA and FITC. The mice were sacrificed 2 h later, 
and  mononuclear  cell  suspensions  were  prepared  from  the 
spleens  and  lymph  nodes  (popliteal,  inguinal,  mesenteric, 
and axillary). The single cell suspensions were fixed with par-
aformaldehyde and analyzed for FITC-positive cells by flow 
cytometry, or stained with phycoerythrin-labeled anti-mouse 
CD11b, CD11c, or Gr-1 monoclonal antibodies (BD pharmin-
gen,  San  Diego,  CA),  after  blocking  the  FcR-binding  an-
ti-CD16/CD32  monoclonal  antibody  (clone  2.4G2),  as  de-
scribed  previously  (18).  Flow  cytometry  was  performed  on 
a  FACS  Cantor  (Becton-Dickinson).
RESULTS
Formulation and characteristics of nano- and micro-
particles
Table I lists the different formulation conditions used to pre-
pare nano- and microparticles along with their mean particle 
size, polydispersity index, zeta potential and protein loading 
efficiency. As expected, increasing the homogenization speed 
resulted in smaller sized NPs. The application of sonication 
energy  (500  W,  30  kHz)  during  homogenizing  of  the  two 
phases, the ethyl acetate phase containing PLGA and water 
phase containing OVA, further decreased the size of the re-
sulting NPs. The mean OVA content was determined using 
a  micro-bicinchoninic  acid  assay  kit  after  lysing  the  NPs  in 
a lysis buffer, and was 22.0∼24.8%. The surface morphology 
of the NPs was visualized by scanning electron microscopy, 
and Fig. 1A shows a representative image of the NPs with 
an average size of 1.1μm. The stability of the NPs was ex-
amined  by  assessing  the  amount  of  soluble  OVA  released 
from the NP. Fig. 1B gives a representative experimental re-
sult, which was performed using the NPs with a mean size 
of 1.1μm. The OVA entrapped within the NPs was not re-
leased from the NPs for at least one week from the NPs if 
the  NPs  were  stored  at  4
oC.
Effect of particle size on cross-presentation
To examine the relationship between the NP size and cross- 
presentation-inducing  activity,  the  NPs  were  incubated  with 
B M - D C s  f o r  2  h  a n d  t h e  D C s  w e r e  f i x e d  w i t h  p a r a f o r -
maldehyde. The amounts of H-2K
b-OVA peptides complexes APC Targeting of Ag with PLGA-nanoparticles
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Figure 2. Effects of the size of NPs on the cross-presentation. DCs 
were incubated with NPs with different mean sizes for 2 h, washed 
with PBS, fixed with paraformaldehyde, and the amounts of OVA 
peptides presented on MHC class I molecules were assessed by a 
LacZ T cell activation assay using OVA specific CD8 T cell 
hybridomas, B3Z cells.
Figure 3. Time-kinetics for the cross-presentation of OVA peptides. 
DCs were incubated with soluble OVA (50μg/ml), OVA-loaded NPs
(50μg/ml), IgG-opsonized OVA-loaded NPs (50μg/ml), or 1 nM 
synthetic OVA peptide (SIINFEKL) for 2 h. The DCs were then washed
with PBS, and were cultured in a medium containing 10% fetal 
bovine serum. At the indicated time points, the DCs were fixed with
paraformaldehyde, and the amounts of OVA peptides presented on 
MHC class I molecules were assessed by a LacZ T cell activation assay
using OVA specific CD8 T cell hybridomas, B3Z cells.
Figure 4. The uptake and biodistribution of NPs injected into the 
mouse peritoneum. C57BL/6 mice were injected i.p. with 100μg of 
NPs containing both OVA and FITC. Mice were sacrificed 2 h later, 
and mononuclear cell suspensions were prepared from the spleens 
(A) and lymph nodes (popliteal, inguinal, mesenteric, and axillary) (B).
The single cell suspensions were fixed with paraformaldehyde and 
analyzed for FITC-positive cells by flow cytometry.
on DCs were assessed using OVA-specific CD8 T cell hybrid-
omas, B3Z cells, which express β-galactosidase in response 
to T cell receptor (TCR) stimulation. As shown in Fig. 2, DCs 
phagocytosed  NPs  in  the  range  of  1.11∼1.44μm  in  size 
were  almost  equally  efficient  in  cross-presenting  OVA  pep-
tides via H-2K
b molecules. The cross-priming-inducing activity 
of NPs decreased dramatically when the mean size of the NPs 
was  reduced  to  0.56μm.  Therefore,  NPs  with  the  average 
size of 1.11μm were chosen for the experiments described 
hereafter.
Effect of opsonization on cross-presentation
The NPs (average size, 1.11μm) were opsonized with mouse 
IgG, and the amounts and time kinetics of OVA peptide pre-
sentation were examined in BM-DCs. In this experiment, the 
amounts of H-2K
b-OVA peptide complexes on DCs were as-
s e s s e d  u s i n g  O V A - s p e c i f i c  C D 8  T  c e l l  h y b r i d o m a s ,  C D 8  
OVA1.3 cells, which express IL-2 in response to H-2K
b-OVA 
peptide (SIINFEKL) complexes. As shown in Fig. 3, DCs in-
cubated with the NPs containing OVA (NP[OVA]) were much 
more  efficient  in  cross-presenting  OVA  peptides  than  those 
incubated with soluble OVA. In particular, the DCs incubated 
with mouse IgG-opsonized NPs (mIgG-NP[OVA]) were much 
more potent in cross-presenting OVA peptides than those in-
cubated with (NP[OVA]). Moreover, the duration of cross-pre-
senting  OVA  peptides  was  also  extended  markedly  in  DCs 
phagocytosed mIgG-NP[OVA]. The DCs phagocytosed mIgG- 
NP[OVA] could present H-2K
b-OVA peptide (SIINFEKL) com-
plexes for 24 h, whereas the DCs incubated with saturation 
amounts of synthetic OVA peptide, SIINFEKL, could present 
H-2K
b-SIINFEKL  complexes  for  only  6  h.
In vivo distribution of NP
Two hours after an intraperitoneal injection of a single dose 
of  100μg  of  FITC-loaded  NPs,  biodistribution  analysis  was 
performed using mononuclear cells isolated from the spleens 
and  lymph  nodes.  As  shown  in  Fig.  4,  the  percentage  of 
FITC-positive  cells  in  the  spleen  and  lymph  node  were  in-
creased dramatically when the mice were injected with mouse 
IgG-opsonized  FITC-loaded  NPs,  compared  to  the  mice  in-
jected  with  unopsonized  FITC-loaded  NPs.  Most  of  the 
FITC-positive cells were in the spleen (approximately 20% in 
the spleen vs. approximately 0.8% in the lymph nodes). To 
e x a m i n e  t h e  c e l l  t y p e  t h a t  i s  p o s i t i v e  f o r  F I T C ,  t h e  m o n o -APC Targeting of Ag with PLGA-nanoparticles
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Figure 5. Cell type analysis for the FITC-positive cells in the spleen 
and lymph nodes. C57BL/6 mice were injected i.p. with 100μg of 
NPs containing both OVA and FITC. The mice were sacrificed 2 h
later, and mononuclear cell suspensions were prepared from the 
spleens (A) and lymph nodes (B), stained with phycoerythrin-labeled
anti-mouse CD11b, CD11c, or Gr-1 monoclonal antibodies, and 
analyzed for FITC-positive cells by flow cytometry.
nuclear cells isolated from the spleens and lymph nodes were 
stained  with  PE-conjugated  anti-mouse  CD11b,  CD11c,  or 
Gr-1  monoclonal  antibodies.  As  shown  in  Fig.  5,  macro-
phages were the major cell type of FITC-positive cells in the 
s p l e e n ,  w h e r e a s  D C s  w e r e  t h e  m a j o r  t y p e  i n  t h e  l y m p h  
nodes.
DISCUSSION
One of the main issues addressed in the present study is the 
elucidation of the optimal size of PLGA particles for the in-
duction of the most potent cross-priming for the antigens en-
trapped inside the particles. Therefore, the present study de-
veloped  methods  to  produce  PLGA-NPs  with  various  mean 
sizes. This method is based on the micromixer-based W/O/W 
solvent evaporation procedure but with a slight modification, 
such as adding sonication energy during the homogenization 
procedure. PLGA-NPs containing almost the same amount of 
ovalbumin  (OVA)  were  generated  but  with  different  mean 
sizes. The efficiency of the NPs to induce cross-presentation 
of the OVA peptides were examined in DCs. The NPs in the 
range of 1.1∼1.4μm in size were the most potent and al-
most  equally  efficient  in  inducing  the  cross-presentation  of 
OVA peptides via H-2K
b molecules in DCs. The size of the 
PLGA-NPs optimal for cross-priming is markedly smaller than 
the  size  of  the  PLGA-NPs  that  were  reported  by  other  re-
searchers to be optimal for phagocytosis by APCs. It PLGA- 
NPs between 3∼10μm in size were optimal for uptake by 
APCs  (13,14).
    One of the unique features of PLGA-NPs is the sustained 
release of the entrapped antigens. In addition, encapsulation 
of the antigen with PLGA would be the protection of the anti-
gen from rapid degradation in the body (1). Therefore, par-
ticles prepared from PLGA have been studied extensively for 
the sustained delivery of therapeutic agents including DNA, 
proteins  and  low  molecular  weight  pharmacological  agents 
used as vehicles to facilitate antigen delivery to phagocytes 
(1,2).  Moreover,  PLGA-NPs  are  easily  conjugated  with IgG. 
Coating  the  PLGA-NPs  with  mouse  IgG  is  expected  to  de-
crease the uptake of NPs by neutrophils while increasing the 
uptake of NPs by Fcγ receptor (FcγR)-positive cells, such 
a s  D C s  a n d  m a c r o p h a g e s .  T h e r efore,  IgG-opsonized  OVA- 
containing PLGA NPs with a average size of 1.1μm would 
be  the  best  vehicle  for  delivering  protein  antigens  to  pro-
fessional APCs in vivo. This hypothesis was confirmed by the 
experiments  described  in  this  manuscript.  Throughout  this 
study, IgG-opsonized OVA-containing PLGA-NPs were found 
to be the superior means for inducing the cross-presentation 
o f  O V A  p e p t i d e s  i n  D C s .
    The reason this study focused on the cross-presentation-in-
ducing activities of the PLGA-NPs in the present study is that 
the  importance  of  enhancing  cross-presentation,  which  was 
first demonstrated in the generation of CTL responses to mi-
nor histocompatibility antigens (19), has now been demon-
s t r a t e d  t o  b e  a n  e s s e n t i a l  m e c h a n i s m  f o r  t h e  g e n e r a t i o n  o f  
CTL responses against tumor cells, transplanted cells, bacteria 
and even viruses (20-23). The present study also showed that 
DCs phagocytosed IgG-opsonized OVA-containing PLGA-NPs 
can present OVA peptides for the most extended time peri-
ods, compared to any other means used in this study. In ad-
dition,  IgG-opsonized  OVA-containing  PLGA-NPs  were  cap-
t u r e d  e f f i c i e n t l y  b y  p r o f e s s i o n a l  A P C s  i n  t h e  s p l e e n  a n d  
lymph  nodes  when  injected  intraperitoneally.
    Overall, these results show  that IgG-opsonized PLGA-NPs 
with  a  mean  size  of  1.1μm  would  be  the  choice  of  bio-
degradable carriers for the targeted-delivery of protein anti-
gens  for  cross-priming  in  vivo.APC Targeting of Ag with PLGA-nanoparticles
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